The possible repurposing of tocilizumab, a humanized antibody against IL-6 receptor, and anakinra, a recombinant IL-1 receptor agonist, for COVID-19 therapy has been under intensive research [113,114] while the IL-6 antagonist sarilumab (NCT04315298), the TNF-α suppressor thalidomide (NCT04273529, NCT04273581) and methylprednisolone (NCT04273321, NCT04263402) are notable examples of anti-inflammatory pharmaceuticals undergoing trials for their potent applications in severe SARS-CoV-2 infections. The gene discussed is IL6; the disease is COVID-19.